The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2016 | Pembrolizumab and the significance of PD-L1 for lung cancer
Roy Herbst, MD, PhD of Yale School of Medicine, New Haven, CT talks about pembrolizumab and the importance of the PD-L1 biomarker. Prof. Herbst explains that the biomarker does help discriminate patients who will benefit most from the drug. He further explains that patients should now be tested for PD-L1 at diagnosis and those who are PD-L1 positive will receive pembrolizumab and those who are PD-L1 negative will receive other treatment.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
